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Abstract: Muscle regeneration, characterized by the activation and proliferation of satellite cells
and other precursors, is accompanied by an inflammatory response and the remodeling of
the extracellular matrix (ECM), necessary to remove cellular debris and to mechanically support
newly generated myofibers and activated satellite cells. Muscle repair can be considered concluded
when the tissue architecture, vascularization, and innervation have been restored. Alterations in these
connected mechanisms can impair muscle regeneration, leading to the replacement of functional
muscle tissue with a fibrotic scar. In the present review, we will discuss the cellular mediators of
fibrosis and how the altered expression and secretion of soluble mediators, such as IL-6 and IGF-1,
can modulate regulatory networks involved in the altered regeneration and fibrosis during aging
and diseases.
Keywords: skeletal muscle; fibrosis; muscle regeneration; Duchenne muscular dystrophy; aging;
Interleukin-6; insulin-like growth factor 1
1. Introduction
Skeletal muscle fibrosis is a clinically relevant event that occurs under different physiopathologic
conditions, such as aging and muscle diseases, or as a secondary outcome of traumatic events [1–3].
The deposition of fibrotic tissue is generally due to the impaired muscle regeneration, associated to
an altered activity and balance of different cell components in skeletal muscle tissue [3,4]. The intimate
relation between myogenic and non-myogenic progenitors, together with the mechanical connections
and biochemical communication between resident cell populations, constitute a network of signaling
pathways necessary to maintain muscle homeostasis and/or to guide an efficient regenerative
process [5–7].
Mounting evidence indicates that multiple factors contribute to the alteration of tissue homeostasis,
leading to the loss of the regenerative capacity of skeletal muscle and, thus, to fibrotic events [3,4].
The altered expression and secretion of soluble mediators, including cytokines and growth factors,
can impinge cell–cell communication, affecting their physiological activity. In addition to the pivotal role
exerted by satellite cells (SCs) and the activity of immune cells, other precursors and stem cell populations,
either residing within the muscle or be recruited via the circulation in response to injury, can contribute
to muscle regeneration. Among these, muscle-resident non-myogenic cells, such as fibro-adipogenic
progenitors (FAPs), are determinant components of muscle niches contributing to the maintenance as well
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as to the alteration of the homeostatic environment upon physiologic or pathologic conditions [8,9].
FAPs are a source of a suite of soluble factors, including Interleukin-6 (IL-6) and the Insulin-like growth
factor-1 (IGF-1), supporting satellite cell proliferation and differentiation [8,10]. In contrast, under
pathologic conditions (i.e., muscular dystrophies) or during aging, the loss of homeostatic signaling
can lead to SC alteration and to the fibro-adipogenic differentiation of FAPs [11,12]. A wealth of works
supported the critical role of IGF-1 and IL-6 in muscle regeneration and disease. IGF-1 and controlled
levels of IL-6 exert a pro-myogenic activity, whereas increased plasma levels of IL-6 have a detrimental
impact on muscle homeostasis [13–17]. In this review, we focus on the main cellular and molecular
players regulating the balance between muscle regeneration and fibrosis. In particular, we report insights
into the role of IL-6 and IGF-1 in modulating the regulatory networks involved in the altered regeneration
and fibrosis during aging and diseases.
2. Cellular Mediators of Regenerative Fibrogenesis and Fibrosis
Muscle regeneration is a homeostatic process in which the different phases involved in muscle
healing, namely inflammation, satellite cells activation, remodeling, and maturation, must be finely
regulated. Of note, satellite cells represent the main player in muscle regeneration; nevertheless,
their activity can be modulated by different cell populations and precursors (Figure 1) [18–22].
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and non-myogenic progenitors (FAPs) are involved in the removal of cell debris and the release of
soluble mediators, like IL-6 and IGF-1, stimulating stem cell activity. The regenerative process is
accompanied by the enhanced deposition and remodeling of the extracellular matrix (ECM), necessary
to mechanically support newly generated myofibers and activated SCs. (b) Chronic degenerative
stimuli can induce the alteration of interconnected mechanisms regulating cell populations in muscle
niches. Indeed, cell populations involved in the physiologic response to muscle damage are
the same players in the shift between the regeneration of functional tissue and the deposition of
a fibrotic scar. FAPs and fibroblasts, which are a source of elevated levels of IL-6, can undergo
deregulated proliferation, prevailing on SCs and driving the excessive deposition of ECM components.
Moreover, elevated levels of IL-6 can induce a sustained proliferation of SCs and can impinge their
myogenic differentiation. These alterations result in the production of fibrotic tissue at the expense of
regenerative myogenesis. FAPs: Fibro-adipogenic progenitors; ECM: Extracellular matrix; SCs: Satellite cells;
IGFBP: IGF binding protein.
Satellite cells, described by Mauro and Katz and identified as CD34pos
/α7-integrinpos/Sca1neg/CD45neg/CD31neg quiescent stem cells residing in a specialized niche,
represent the myogenic stem cell pool responsible for the formation of new myofibers and for
the repair of damaged muscle (Figure 1a) [23,24]. SC activity is known to be influenced by signals
derived from the surrounding environment and by interactions with other cellular components
of muscle niche [6,7,22]. In particular fibro-adipogenic progenitor cells (FAPs), identified as
CD34pos/α7-integrinneg/Sca1pos/CD45neg/CD31neg cells, expressing cell-surface platelet-derived
growth factor receptor alpha (PDGFRα) are non-myogenic interstitial progenitors involved in
the establishment of a dynamic environment supporting muscle regeneration, satellite cells
proliferation, and differentiation [8,9,25,26].
The contribution of FAPs as regulators of muscle niches has been proposed, and the functional
ratio between FAPs and SCs appeared as a prerequisite to guarantee muscle homeostasis [8,27,28].
Indeed, satellite cells and FAPs present a reciprocal regulation in muscle tissue, and their
interactions are thought to be critical for an efficient regenerative process. It has been suggested
that the reduction in the percentage of FAPs in aged muscles might result in an alteration in muscle
homeostasis [11], whereas the presence of a significant number of FAPs, expressing high levels of IGF-1
and follistatin, in the extraocular muscles (EOMs) might contribute to the creation of a qualitative
environment for SC activity, protecting the EOMs from age- and disease-related changes [11].
FAPs, which are normally quiescent in healthy muscles, actively proliferate following tissue
damage, secrete a suite of factors that stimulate myogenesis, and are also known to transiently
produce ECM proteins necessary to support and guide regenerative myogenesis (Figure 1a). It has
been reported that the administration of Nilotinib, a tyrosine kinase inhibitor targeting PDGFR
and TGFβ pathways critical for FAPs activity, severely affects regeneration in a mouse model of
muscle damage [29]. However, it is worthy to indicate that Nilotinib, the drug used in the study by
Fiore et al. (2016), is a broad-spectrum tyrosine kinase inhibitor and most likely targeted multiple
cell types. Although FAPs can play a critical role in SC behavior and muscle regeneration, their
activity must be transiently and finely regulated. The excess of FAPs, resulting from a physiologic
regeneration, is subject to clearance mechanisms mainly mediated by apoptotic stimuli derived from
immune cells and satellite cells [25,30]. In contrast, in several pathologic conditions, satellite cells
or other precursor cells are thought to be defective in the production of factors that control FAPs
activity. The altered activity of FAPs in a deregulated muscle environment, characteristic of chronic
diseases, can contribute to the extensive ECM deposition and fatty tissue accumulation (Figure 1b) [31].
An aberrant accumulation and differentiation of FAPs have been described in aged muscles and in
several models of chronic, degenerative diseases including Duchenne muscular dystrophy (DMD)
and Amyotrophic lateral sclerosis (ALS).
It has been reported that severely denervated muscles presented a consistent accumulation of FAPs
promoting a pro-fibrotic and pro-atrophic action in skeletal muscle [8,31,32]. An elective mechanism
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underlining the altered phenotype of denervated muscle-derived FAPs is the persistent stimulation
of an IL-6 signaling pathway, since an enhanced expression and activity of IL-6 has been observed
in FAPs isolated from different models of denervation. Moreover, the inhibition of STAT3, the main
mediator of the IL-6 pathway, in a murine model of ALS (SOD G39A mice) prevented muscle atrophy
and fibrosis [32]. Accordingly, the correlation between FAPs and IL-6 was also highlighted in the murine
model of Duchenne muscular dystrophy (mdx mouse), a genetic muscle disease characterized by
the progressive degeneration of muscle tissue, by inefficient regeneration, and by fibrotic/fatty
tissue deposition. The overexpression of circulating IL-6 in mdx dystrophic mice (mdx/IL-6 mice)
induced a significant exacerbation of the dystrophic phenotype with the long-term exhaustion of
the satellite cell pool and the accumulation of FAPs [33]. It has been proposed that deregulated FAPs
not only can prevail on satellite cell activity and can alter muscle niche but have been also indicated
as potential progenitors of myofibroblasts and adipocytes, contributing to fibrosis and adipose tissue
accumulation [34,35]. Interestingly, it has been recently reported that FAPs presenting primary cilia
are involved in the deposition of fatty tissue in skeletal muscle upon injury or in cases of muscular
dystrophy (Figure 1b, lower panel) [35,36]. Nonmotile cilia are responsible for the transduction of
specific signals as the ciliary-Hedgehog (Hh) pathway that has been involved in both muscle repair
and adipogenic differentiation of FAPs [35–38]. In contrast, the absence of cilia in FAPs stimulated
myogenesis after injury and prevented adipogenesis in dystrophic muscles, highlighting a novel
potential mechanism contributing to the regulation of muscle regeneration.
Although FAPs are critical players for muscle function and SC activity, the mechanism determining
deregulated FAP activation remains to be fully elucidated, and the contribution of FAPs to skeletal
muscle alteration is still debated.
Reciprocal Regulation of Fibroblasts and Satellite Cells Activity
The production and secretion of extracellular matrix (ECM) components mainly depends on
fibroblasts residing in muscle interstitium. The quality and abundance of ECM proteins are known to
influence stem cell quiescence and activation within the muscle niche. However, different findings
indicated that ECM deposition can be directly or indirectly regulated by other cell types as myogenic
stem cells and progenitors (Figure 1) [39]. Satellite cells and fibroblasts are in close relation in
regenerating muscles, since the remodeling of connective tissue is crucial to guarantee the mechanical
support and biochemical signals necessary to activated stem cells. The specific role of fibroblasts
during muscle regeneration has been poorly investigated because of the lack of specific markers.
Nevertheless, a pioneer study, although not conclusive, suggests that the proliferation of connective
tissue fibroblasts, identified by Tcf4 expression, strictly accompanies the expansion of activated
Pax7pos SCs after injury [40]. Although Tcf4 is also expressed by myoblasts and other cell types
in adult skeletal muscle, these interstitial Tcf4pos cells have been shown to express other markers of
fibroblasts as PDGFRα and αSMA but not markers of myoblasts and macrophages as Pax7, MyoD,
and F4/80. Since fibroblasts were found in close association with satellite cells and regenerating
fibers, it is likely that their interactions play a role in the regulation of muscle repair. To support
this hypothesis Murphy and colleagues performed a genetic manipulation of Tcf4pos fibroblasts in
injured skeletal muscle, observing a significant alteration in satellite cell behavior during regeneration.
In particular, the dramatic reduction of fibroblasts in regenerating muscles led to a precocious
SC differentiation impinging their expansion [40]. These data are in accordance with evidence
demonstrating the involvement of fibroblasts not only in the deposition of ECM but also as a source
of soluble factors that might regulate myogenic cells activity. For instance, fibroblasts are known
to secrete growth factors, lipid mediators and cytokines as IL-6, involved in the regulation of SC
proliferation and muscle metabolism [41]. However, the deregulated activity of fibroblasts under
pathologic conditions can contribute to the alteration of homeostatic responses in skeletal muscle
(Figure 1b, lower panel). It has been reported that IL-6 can promote the expression of collagen in human
dermal fibroblasts via Gremlin1, a BMP inhibitor with pro-fibrotic actions, able to enhance TGFβ
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signaling pathway [42]. The reciprocal interaction between fibroblasts and muscle stem cells has been
also elucidated by Fry and colleagues that reported how SCs can directly regulate ECM production by
fibrogenic cells. In particular, it has been described that satellite cells can secrete exosomes containing
a specific microRNA, the myoMiR-206, with important implications in muscle regeneration [43,44].
SC-derived exosomes have been shown to regulate collagen synthesis through the miR-206-mediated
inhibition of Rrbp1, a master regulator of collagens expression [39]. These studies highlighted
a potential mechanism by which SCs can actively modulate the local environment by influencing
the biosynthesis of ECM components, further avoiding an excessive deposition of collagen during
muscle adaptive responses (Figure 1b, lower panel).
If fibroblasts and secreted matricellular proteins have been shown to positively regulate
physiologic muscle regeneration, it has also been reported that alterations in this compartment
contribute to the loss of the muscle regenerative capacity during aging and disease. Changes in
fibroblast features and ECM properties have been detected in aged muscles [2]. In particular,
aged fibroblasts showed a contracted phenotype with nuclear deformation which is known to
participate in the alteration of gene expression [2,45]. In accordance, a recent work by Stearns-Rider
and colleagues showed that fibroblasts from aged muscles display a different expression of the collagen
genes, with an increased expression of metalloproteinase inhibitors compared with ones isolated from
young tissue. The altered composition of ECM and the increased stiffness associated with muscle
aging can, in turn, induce a pathologic phenotype in fibroblasts, stimulating mechano-transductive
signaling as the YAP/TAZ pathway, and can promote the fibrogenic differentiation of muscle stem
cells [2].
The dysregulation of fibroblast activity and excessive ECM production have also been observed
in chronic degenerative disorders as Duchenne muscular dystrophy (DMD). It has been proposed that
the absence of the dystrophin protein may alter the structural and mechanical properties associated
with fibroblasts. In addition, signals deriving from the altered milieu in dystrophic muscles can also
contribute to the deregulated behavior of dystrophin-deficient fibroblasts. In fact, although the precise
contribution of intrinsic and extrinsic alterations in the regulation of fibroblast activity has to be
fully defined, it has been described that this cell population shows a pro-fibrotic phenotype in DMD
(Figure 1b, lower panel) [46]. In particular, different studies from Zanotti and colleagues reported
that primary fibroblasts derived from DMD patients showed a deregulated phenotype characterized
by increased proliferation, altered collagen production, and a marked resistance to apoptosis [46,47].
Moreover, in vitro studies reported that DMD fibroblasts or their conditioned medium can impair
the growth of dystrophic myoblasts. The putative negative impact of DMD fibroblasts on SC activity
has been also related to the increased expression and secretion of the IGF-1 binding protein 5
(IGFBP-5), which might interfere with the pro-myogenic activity of IGF-1, since the neutralization of
IGFBP-5 was able to revert the inhibitory effect of the DMD-fibroblast conditioned medium (Figure 1b,
lower panel) [48].
Collectively these studies suggested that the enhanced fibroblast proliferation and ECM
deposition, together with the altered expression of metalloproteinases and their inhibitors,
can influence the activity of the muscle stem cell reservoir that could, in turn, affect their own
behavior, fostering a fibrotic degenerative loop in dystrophic muscles. To support this hypothesis,
when satellite cells were depleted from healthy overloaded muscles, an extensive ECM deposition
and Tcf4pos cell proliferation occurred, supporting the role of satellite cells in regulating fibroblast
activity [39]. These evidences are coherent with a model in which the alteration of muscle fibroblasts
and consequent modification of ECM properties can negatively influence satellite cell activity and fate.
On the other hand, the progressive exhaustion of the resident stem cell pool in dystrophic muscles,
due to intrinsic SC alterations and continuous cycles of degeneration and regeneration of myofibers,
might allow fibroblasts to prevail on regenerative processes contributing to muscle fibrosis (Figure 1b).
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3. Pro- and Anti-Fibrotic Factors Influencing the Balance between Regeneration and Fibrosis
The activation of fibrogenic pathways represents an adaptive mechanism involved in tissue repair
after injury.
A key regulator of both myogenesis and ECM remodeling is the Transforming growth factor
β (TGFβ), a cytokine with multiple roles in muscle healing and fibrosis [49]. TGFβ is known to
be released by damaged myofibers and acts as a chemotactic factor for hematopoietic cells during
the inflammatory stage of muscle regeneration. In addition, TGFβ has been recognized as a pivotal
mediator of ECM remodeling, being a potent inducer of matricellular protein secretion by fibroblasts
and a negative modulator of metalloproteinases. The physiologic increase of ECM components, due to
TGFβ stimulation, plays an important role in the recovery of muscle architecture during healing,
and its ablation in injured muscles can impair regeneration [49,50]. In contrast, TGFβ overproduction,
that occurs under pathologic conditions, like DMD, is known to induce the excessive deposition
of collagens, contributing to muscle fibrosis [51,52]. The activation of the TGFβ pathway through
Smad3 signaling can also influence the proliferation and differentiation of muscle stem cells, inhibiting
the activation of myogenic regulatory factors [53–56]. Furthermore, it has been observed that myoblasts
overexpressing TGFβ differentiate into myofibroblasts when transplanted in murine muscles [57].
Myostatin is another member of the TGFβ family involved in muscle fibrosis [58]. The action
of myostatin is mediated by a TGFβ-like signaling, involving the activation of the Smad/p38
MAPK/Akt axis, and can stimulate skeletal muscle fibroblast proliferation and the secretion of
ECM proteins [49,58,59]. It has been reported that the genetic ablation of myostatin reduced
fibrotic tissue deposition, favoring muscle regeneration in injured muscles [59]. Myostatin has
been correlated not only to fibroblast proliferation but also to the resistance of DMD fibroblasts to
apoptosis. Of note, the inhibition of myostatin signaling in dystrophic muscles was sufficient to revert
the fibrotic phenotype [60]. Moreover, this myokine has been recognized as an inhibitor of muscle
development and growth, impinging muscle progenitor cell proliferation and differentiation [55,61,62].
Notably, the pro-fibrotic action of myostatin can be counteracted by decorin, a proteoglycan
involved in collagen fibrillogenesis [63]. The administration of decorin has been shown to prevent
myoblast trans-differentiation into myofibroblasts in vivo and has led to the improved recovery
of skeletal muscles after injury [57,64]. The anti-fibrotic action of decorin can be related to
the upregulation of another anti-fibrotic agent, follistatin, which is an inhibitor of myostatin [59].
Indeed, follistatin overexpression improved myogenic differentiation in vitro and muscle regeneration
in vivo, reducing muscle fibrosis [65].
Another cytokine referred as a myokine is IL-6, which is known to play important roles in muscle
regeneration, inflammation, and fibrosis. IL-6 is involved in the regulation of satellite cell activity
promoting the proliferation of activated stem cells, whilst its overexpression can impair myogenic
differentiation and the physiologic resolution of the inflammatory response, fostering pathogenic
changes that result in muscle wasting and fibrosis. Of note, IL-6 has also been correlated to
the inhibition of IGF-1 activity, an anabolic and pro-myogenic factor critical for skeletal muscle
growth and regeneration [66]. Thus, molecular mediators in muscle milieu, like IL-6 and IGF-1,
can play an important role in regulating the balance between muscle regeneration and degeneration.
These niche factors, modulating tissue environment, can act by supporting reparative mechanisms in
injured tissues or can impair, when deregulated, the physiologic response to damage, thus promoting
fibrotic tissue deposition.
4. Interleukin-6: Spectrum of Pro-Fibrotic Actions
IL-6 is a pleiotropic cytokine promptly produced by muscle and other tissues in response to
physiopathological changes including physical exercise, infections, and injury [67]. The positive
and negative roles of IL-6 in tissue homeostasis have been extensively studied and described, and it is
generally accepted that the dual nature of its action is related to the activation of different signaling
pathways [68,69]. The activation of the classical signaling is strictly dependent on the expression
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of the membrane bounded IL-6 receptor alpha (IL6R) in combination with the ubiquitous receptor
gp130. Thus, the canonical signaling is physiologically restricted to those cells expressing IL6R
and is responsible for the induction of anti-inflammatory and pro-regenerative pathways in skeletal
muscle [15,70–72]. A soluble form of IL6R, sIL6R, is able to amplify the spectrum of action of
IL-6, activating the so called trans-signaling with pro-inflammatory and pro-fibrotic implications
(Figure 2) [42,73–76]. Of note, circulating IL-6 levels are undetectable under physiologic conditions but
increase significantly in several diseases associated with inflammation and fibrosis [33,77–79].Cells 2019, 8, x 7 of 18 
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4.1. Immune Response and Fibrosis: A Fatal Interplay
IL-6 is produced by a wide range of immune cells, which are, in turn, highly responsive to this
cytokine. Moreover, the alternative signaling of IL-6, mediated by the sIL6R, can promote a chronic
inflammatory status, influencing the quality of the immune response. In fact, IL-6 is known to
affect the balance between leucocytic populations at the site of inflammation, inducing a shift from
neutrophilic to macrophagic accumulation. A role for IL-6 in regulating T and B lymphocytes has been
also reported, demonstrating that it can induce B and Th17 cells and can inhibit Treg differentiation,
favoring the persistence of the inflammatory response [78,80–82].
According to the pivotal role of IL-6 in promoting the establishment of a chronic inflammatory
environment, it has been described that IL-6 promotes a pro-fibrotic status in a mouse model of
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peritoneal inflammation by impairing the physiologic resolution of the inflammatory response
through the promotion of the T helper 1 immune response [83]. Of note, IL-6 deficient mice were
resistant to repeated inflammation-related fibrosis. In addition, it has been reported that the IL-6
signaling contributes to the development of fibrosis in the sclerodermatous chronic graft-versus-host
disease (Scl-cGVHD), another model of immune-related disease characterized by excessive ECM
deposition in the skin and visceral organs that impair tissue functionality [84]. In light of these
and many other studies, IL-6 blockade clearly appears as a possible strategy to avoid fibrotic tissue
degeneration. Pharmacological inhibitors of IL-6 signaling, which are already used in the clinic to treat
chronic disorders like rheumatoid arthritis, have been shown to induce beneficial effects in a suite
of experimental models of degenerative diseases [42,85–87]. For instance, Le Huu and colleagues
demonstrated that the inhibition of IL-6 trans-signaling, through a neutralizing antibody direct against
IL6R (MR16-1), reduced the extent of fibrosis in the skin, lungs, and liver from Scl-cGVHD mouse
models by enhancing the number of T regulatory cells [84].
Chronic inflammatory changes and fibrogenic events also characterized the skeletal muscle
environment in muscular dystrophies, where the constant induction and amplification of
pro-inflammatory pathways interfered with regenerative signaling, contributing to muscle fibrosis.
In this pathologic context, recent works highlighted the involvement of sustained IL-6 levels in inducing
muscle wasting. It has been reported that elevated circulating levels of IL-6 are the determinant for
the development of a severe phenotype in mdx mice, more closely approximating the human DMD
pathology [33,77,79].
Of note, IL-6 is able to actively induce an extensive production and secretion of acute phase
proteins (APPs), including fibrinogen (Figure 2) [88]. Fibrinogen can increase the permeability of blood
vessels at the inflammatory lesion where it is enzymatically converted to polymeric fibrin [89–91].
The excessive fibrinogen accumulation and fibrin deposition have been reported in dystrophic muscles
from DMD patients and mdx mice [92]. In particular, Vidal and colleagues observed a significant
correlation between fibrin/ogen accumulation and fibrosis in DMD muscles, suggesting a role
for fibrin/ogen in promoting pathologic fibrogenesis (Figure 2). IL-6, which is known to be
significantly increased in DMD sera and muscles, can induce fibrinogen expression not only through
the STAT3-mediated downstream pathway but also by directly interacting with responsive elements
upstream the fibrinogen gene [93,94]. Fibrinogen expression can, in turn, induce collagen deposition by
increasing TGFβ expression in mdx mice and stimulate a macrophage-dependent cytokine production
(including IL-6), thus fostering a pro-fibrotic mechanism in DMD muscles (Figure 2). Other critical
IL-6/STAT3-induced factors are haptoglobin (Hp) and Hepcidin, physiologically involved in the iron
homeostasis, which are known to contribute, when deregulated, to the inflammation-related iron
alteration [94–96]. Haptoglobin is a protective factor against tissue damage derived from free
hemoglobin and consequent oxidative stress. In particular, Hp was reported as an anti-inflammatory
factor inducing the expression of heme oxygenase (Ho-1) and IL-10. However, recent studies
revealed that elevated levels of Hp can further induce IL-6 expression, possibly amplifying pathologic
changes during persistent inflammation [94,97]. In fact, Hp has been recently proposed as a serum
biomarker of diagnosis/prognosis for DMD [98]. Accordingly, circulating levels of both IL-6
and Hp strongly increased during chronic inflammatory conditions such as rheumatoid arthritis
(RA) and DMD [98–102]. Although IL-6 fulfills beneficial roles in host defense and tissue repair,
inducing the systemic acute phase response, it is plausible that a sustained stimulation of IL-6 signaling
pathway could affect muscle homeostasis.
Of note, a phenotypical and functional improvement of dystrophic muscles has been observed under
IL-6 trans-signaling inhibition [100]. Similar results have been recently obtained in dystrophin-/utrophin
-deficient mice (dKO), a severe model of DMD [103]. Notably, Wada and colleagues revealed a reduced
extent of muscle fibrosis and a significant down-modulation of pro-fibrotic factors, as periostin and Timp1,
in adult dKO mice treated with neutralizing IL6R antibody compared to untreated mice [103].
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Altogether these data indicated that IL-6 signaling can induce pro-fibrotic pathways in skeletal
muscle and other tissues by promoting the establishment of a chronic pro-inflammatory milieu.
Unresolved inflammation can, in turn, impede a physiologic regenerative process and drive fibrotic
tissue deposition. Considering these evidences, IL-6 trans-signaling blockade appeared as a potential
therapeutic approach with anti-fibrotic effects in treating inflammatory-related diseases.
4.2. Oxidative Stress
Another proposed mechanism underlining tissue fibrosis is the imbalance between reactive
oxygen species (ROS) and the endogenous antioxidant defense. Mounting evidence supports
the hypothesis of a “redox-fibrosis” occurring in aging- and inflammation-related diseases [104,105].
Excessive ROS production and markers of oxidative damage have been reported in several pathologic
conditions as liver and lung fibrosis and in muscle wasting diseases like DMD. In particular,
ROS production in skeletal muscle derives from a suite of cellular sources including immune cells,
fibroblasts, endothelial cells, and myofibers which express the NAD(P)H oxidase complex (NOX)
and are able to convert molecular oxygen to oxygen radicals (Figure 2). These highly reactive molecules
are considered secondary mediators in different signaling involved in metabolic and regenerative
pathways, and their production and persistence are finely regulated. In fact, the extent of ROS
production is generally counterbalanced by antioxidant systems mainly regulated by Nrf2 transcription
factor, which neutralizes free radicals. In particular, under oxidative conditions, Nrf2 is released
by its regulator Keap1, acquiring the ability to translocate in the nuclear compartment and to
regulate the gene expression of the main antioxidant enzymes, deputed to the neutralization of
superoxide and its derivates [106–108]. Thus, the occurrence of oxidative stress can be promptly
prevented by the maintenance of the homeostatic balance between oxidant and antioxidant mediators.
However, ROS accumulation and antioxidant system impairment have been described under
pathologic conditions leading to oxidative damage.
An altered redox status has been shown to be related to fibrosis persistence in aged mice.
In particular, the enhanced expression of NOX and the depressed Nrf2-dependent antioxidant
response contributed to the impaired capability of aged mice to resolve lung fibrosis, whereas targeting
NOX4 was possible to reverse the fibrotic phenotype [109]. The involvement of NOX-related redox
signaling in pro-fibrotic pathways has been also described in skeletal muscle tissue. NOX-dependent
ROS production in muscle cells has been shown to be strictly involved in the pro-fibrotic action of
Angiotensin II, an oligopeptide increased in fibrotic diseases which is able to induce the expression of
a suite of ECM components including fibronectin and collagen-III (Figure 2) [110].
A significant increase in NOX2 expression and activity has been also described in DMD
patients and dystrophic murine models. Of note, recent works revealed a pivotal role of IL-6 in
inducing detrimental effects on the NOX2/Nrf2-dependent redox balance in dystrophic muscles.
It has been demonstrated that enhanced serum levels of IL-6 in mdx mice (mdx/IL-6 model)
dictated a perturbation of redox signaling cascades in dystrophin-deficient muscles even prior to
the necrotic phase and during the progression of pathology [79]. Although dystrophic muscles are
able to induce an active antioxidant response to counter the detrimental effects of ROS, the sustained
expression of IL-6 in mdx/IL-6 mice stimulated ROS production by enhancing the NOX2 expression
and impinged the Nfr2-dependent antioxidant defense, repressing the expression of both Nrf2
protein and Nrf2-dependent genes. [77,79]. A similar expression pattern of oxidant and antioxidant
mediators was observed in DMD patients, characterized by high expression levels of IL-6 during
the progression of pathology. Furthermore, data from our studies highlighted IL-6 as a possible link
between inflammation and ROS production in dystrophic muscles [77,79]. In fact, sustained stimulation
of IL-6 signaling not only impairs the endogenous antioxidant response in mdx muscles but also
induces the upregulation of NOX2 and NF-kB, a critical mediator of the inflammatory response,
fostering pathogenic mechanisms involved in muscle wasting and fibrosis (Figure 2) [33,77,108].
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5. IGF-1 As a Modulatory Factor in Muscle Niche, Promoting Regenerative Events
An efficient muscle repair after injury strictly depends on the activation and completion of a proper
regenerative program. Molecular mediators supporting satellite cell survival and differentiation
could play a critical role in the promotion of a functional tissue recovery at the expense of fibrosis
(Figure 1). IGF-1 is a growth factor with anabolic functions that has been implicated in muscle growth,
hypertrophy, and regeneration [16,111–114]. IGF-1 is secreted by a suite of cell populations within
the muscle niche, including satellite cells, myofibers, fibroblasts, and inflammatory cells, and likewise,
cells are responsive to this peptide hormone [11,115–117]. In fact, the IGF1 receptor (IGF1R)
is ubiquitous and activates molecular cascades critical for muscle homeostasis such as protein synthesis,
muscle cell survival, and muscle activity [118,119]. After muscle injury, monocytes/macrophages
recruited at the site of the lesion represent a primary source of IGF-1 [116,117]. The balance between
different subpopulations of macrophages is essential for physiologic muscle regeneration after
damage [18,21,120,121]. In particular, macrophages are a heterogenous cell population with a range of
activation-related skills [122–124]. M1 macrophages, expressing surface markers, like CD68 and Ly6C,
are considered pro-inflammatory cells participating in the early stages of muscle regeneration by
removing cell debris and releasing cytokines able to amplify the inflammatory response and to activate
muscle stem cells [122,125–127]. Alternative activated macrophages (M2), mainly characterized by
markers as CD163, CD206, and CX3CR1, are involved in the resolution of inflammation and in
the promotion of the myogenic program and ECM remodeling and play a role in the later stages of
tissue repair [122,126,127]. In a recent work, Tonkin and colleagues reported that both Ly6C and CD206
positive macrophages contribute to IGF-1 production in injured muscles at the stage of the transition
between inflammation and regeneration (day 5 after damage). The genetic ablation of IGF-1 in
murine monocytes/macrophages (ϕIGF-1 CKO mouse) resulted in impaired muscle regeneration after
an injury with a reduced size of regenerated myofibers, expanded interstitial spaces, and fatty tissue
deposition [117]. In addition, ϕIGF-1 CKO mice presented an imbalance between the macrophagic
subpopulation with a significant accumulation of Ly6C cells and a reduced presence of CD206 cells,
indicating that the loss of IGF-1 expression could induce an alteration of the quality of the inflammatory
response at the site of tissue lesion, affecting the switch from inflammation to regeneration. These data
are consistent with a series of studies highlighting the role of IGF-1 in promoting muscle regeneration
through the stimulation of myoblast proliferation and differentiation and by the modulation of muscle
environment (Figure 1a). For instance, we demonstrated that the enhanced expression of mIGF-1,
the local isoform of IGF-1, in skeletal muscle (MLC/mIGF-1 mouse) accelerates regenerative processes
after muscle injury, creating a qualitative environment able to efficiently support a proper tissue
repair. In particular, a murine muscle in which mIGF-1 was overexpressed rapidly regenerated after
damage, reducing muscle fibrosis, and presented a modulated inflammatory milieu characterized by
the reduced expression of pro-inflammatory cytokines and chemokines as TNFα, IL1β, and MIF [113].
The IGF-1 signaling pathway is known to be altered in skeletal muscles during aging when
the decline of the regenerative capability of muscle tissue occurs [128]. In addition, reduced levels of
circulating IGF-1 have been described in serum from elderly individuals with a positive correlation
with the decline of protein synthesis and muscle mass and increased levels of myostatin and fatty tissue
accumulation [129–133]. In contrast, the overexpression of the mIGF-1 transgene revealed a protective
action of this specific isoform against skeletal muscle decline during senescence in mice [134].
Senescent transgenic mice (24 months of age) displayed attenuated signs of age-related changes in
muscle phenotype compared to age-matched wild-type mice, retaining the ability to promote functional
regenerative mechanisms [134]. Moreover, the stimulation of the Akt/mTOR axis downstream of
IGF-1 signaling by Losartan, an inhibitor of Angiotensin II receptor (AT1), was able to counteract
the occurrence of muscle atrophy due to disuse in aged mice [135]. Losartan-treated sarcopenic mice
presented a reduced extent of fibrotic tissue deposition after injury, exhibiting a preserved muscle
architecture upon damaging events compared to control mice [135].
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The ability of IGF-1 to preserve the structural integrity of muscle tissue and to support
regenerative mechanisms has been also elucidated under pathologic conditions as muscular
dystrophies. The combination of IGF-1 overexpression and Losartan treatment significantly
ameliorated the pathologic muscle phenotype in murine models of Lama2-related muscular dystrophy
(MDC1A) by reducing inflammation and fibrosis and by preserving tissue structure and function [136].
The enhanced expression of mIGF-1 selectively in skeletal muscles of dystrophic mice influenced
the offset between tissue degeneration and regeneration. In particular, it has been demonstrated that
mdx/mIGF-1 mice not only presented a reduced myonecrosis of the diaphragm muscle, the most
compromised muscular district in DMD, but also displayed functional hypertrophy. In addition,
although IGF-1 has been recognized as a stimulator of fibroblast activity, mdx/mIGF-1 mice revealed
a reduced extent of muscle fibrosis. The well-described pro-myogenic activity of IGF-1 in skeletal
muscle can also contribute to the stabilization of dystrophic muscle phenotype by promoting survival
pathways and molecular circuits, leading to a complete myogenic differentiation of regenerated fibers
along with the maintenance of their terminally differentiated status [137,138]. Despite controversial
indications about the anti-fibrotic role of IGF-1 in muscle tissue, a recent work highlighted a possible
correlation between circulating levels of irisin, IGF-1 expression, and the improved muscle mass
in human, or the amelioration of dystrophic muscle in mice [137,139–141]. Irisin is a myokine
secreted in response to physical exercise able to induce muscle growth and to promote IGF-1
expression in human myocytes [140]. Reza and colleagues reported that irisin injection in mdx
mice resulted in a significant reduction of muscle necrosis and fibrosis, enhancing the stability
of the dystrophin-deficient sarcolemma [142]. Of note, the upregulation of IGF-1 was proposed
as a possible molecular mechanism underlining irisin action and mediating its modulatory impact on
dystrophic muscle.
6. Conclusions
The enhanced production and deposition of ECM components represent a critical stage
of the adaptive response of muscle to tissue injury, directed to the generation of mechanical
and biochemical support for regenerating fibers. Regenerative fibrogenesis is the result of
a well-coordinated network of signals deriving from different cell contributors, and it is strictly required
to efficiently repristinate the proper architecture of the functional muscle tissue. When the orchestrated
pattern of fibrogenic stimuli is disturbed, as under physiopathologic conditions like aging and muscular
dystrophies, tissue fibrosis occurs, contributing to the progressive impairment of muscle function.
Thus, the study and identification of molecular and cellular mediators involved in the alteration
of fibrogenic events appear of relevant clinical interest. Among the factors, IGF-1 and IL-6 can
be considered as central mediators in the muscle niche, influencing the balance between muscle
regeneration and fibrosis. In particular, IGF-1 can favor regenerative myogenesis and support
the robustness of myofibers. On the other hand, IL-6 has been recognized as a pro-inflammatory
factor with pro-fibrotic actions. Elevated levels of IL-6 can deeply alter skeletal muscle milieu,
affecting the activity and quality of cellular interactors in muscle regeneration and contributing
to the fibrotic maladaptive response to tissue damage. Although a wealth of studies highlighted
even more mechanisms regulating muscle regeneration/fibrosis, a comprehensive understanding
of the complex interplay between the main cellular interactors in muscle niche is still lacking.
Thus, future studies are required to develop specific therapeutic strategies in order to restore
the physiologic relationship among cell mediators of muscle regeneration, limiting the extent of fibrosis.
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